Capricor Therapeutics Faces Securities Class Action Deadline

A securities class action lawsuit has been filed against Capricor Therapeutics, alleging the company failed to adhere to pre-specified blinding and protocol procedures for its Phase 3 HOPE-3 trial. Investors affected by these claims have a deadline of September 28, 2026, to join the legal action.

The lawsuit centers on claims that Capricor Therapeutics did not follow established protocols during the execution of the HOPE-3 trial. Further scrutiny emerged as the U.S. Food and Drug Administration (FDA) noted that the final study protocol deviated from the associated statistical analysis plan. These deviations could potentially impact the validity and interpretation of the study's outcomes.

The class action is open to shareholders who may have suffered financial losses due to the company's alleged conduct. The final date for investors to opt into the lawsuit is September 28, 2026. Affected parties are advised to consult with legal counsel to understand their rights and obligations in this matter.

This case underscores the importance of rigorous adherence to research protocols and transparency within the pharmaceutical industry, as well as the role of regulatory oversight in ensuring scientific integrity.